Your browser doesn't support javascript.
loading
Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.
Thomas, K S; Apfelbacher, C A; Chalmers, J R; Simpson, E; Spuls, P I; Gerbens, L A A; Williams, H C; Schmitt, J; Gabes, M; Howells, L; Stuart, B L; Grinich, E; Pawlitschek, T; Burton, T; Howie, L; Gadkari, A; Eckert, L; Ebata, T; Boers, M; Saeki, H; Nakahara, T; Katoh, N.
Afiliação
  • Thomas KS; Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.
  • Apfelbacher CA; Institute of Social Medicine and Health Systems Research (ISMHSR), Otto von Guericke University Magdeburg, Magdeburg, Germany.
  • Chalmers JR; Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.
  • Simpson E; Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA.
  • Spuls PI; Department of Dermatology, Amsterdam Public Health, Infection and Immunity, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Gerbens LAA; Department of Dermatology, Amsterdam Public Health, Infection and Immunity, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Williams HC; Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.
  • Schmitt J; Center for Evidence-based Healthcare, Medical Faculty Carl Gustav Carus, Dresden, Germany.
  • Gabes M; Medical Sociology, Department of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany.
  • Howells L; Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.
  • Stuart BL; Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Grinich E; School of Medicine, Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA.
  • Pawlitschek T; School of Medicine, Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA.
  • Burton T; Patient Representative (independent), Nottingham, United Kingdom.
  • Howie L; Global Parents for Eczema Research, Brisbane, Australia.
  • Gadkari A; Health Economics and Outcomes Research, Boehringer Ingelheim Inc, Germany.
  • Eckert L; Global Dupixent Business Partner, sanofi GHEVA, 1 av. Pierre Brossolette, 91 380, Chilly Mazatin, France.
  • Ebata T; Chitofuna Dermatology Clinic, Tokyo, Japan.
  • Boers M; Department of Epidemiology and data Science; Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands.
  • Saeki H; Department of Dermatology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, Japan.
  • Nakahara T; Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Katoh N; Department of Dermatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Br J Dermatol ; 2020 Nov 11.
Article em En | MEDLINE | ID: mdl-33179283

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Qualitative_research Idioma: En Revista: Br J Dermatol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Qualitative_research Idioma: En Revista: Br J Dermatol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido